Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to 15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation disorders and/or hyperandrogenemia, and often accompanied by insulin resistance and other metabolic abnormalities. Visceral fat dysfunction is an important factor in the onset of PCOS. GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk. The purpose of this study was to compare whether the combined treatment of GLP-1 receptor agonists and calorie restrict diet reduced more visceral fat of overweight/obese patients with PCOS at the same weight loss (7%) compared with calorie restrict diet alone.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
68
GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk.
Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.
Shanghai Tenth People' Hospital
Shanghai, Shanghai Municipality, China
the change in visceral adipose tissue
the change in visceral adipose tissue (pretreatment-post-treatment) after achievement of the weight loss target
Time frame: until achievement of the weight loss target,an average of 12 weeks
menstrual frequency
number of menstruation in a year
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
systolic blood pressure
systolic blood pressure (SBP), mmHg
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
diastolic blood pressure
diastolic blood pressure (DBP), mmHg
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
fasting plasma glucose
fasting plasma glucose (FPG), mmol/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
postprandial plasma glucose
postprandial plasma glucose (PPG), mmol/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
fasting insulin
fasting insulin (FINS), mU/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
postprandial insulin
postprandial insulin (PINS), mU/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
glycosylated hemoglobin A1c
glycosylated hemoglobin A1c (HbA1c), %
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
homeostasis model assessment of insulin resistance
homeostasis model assessment of insulin resistance (HOMA-IR)
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
alanine aminotransferase
alanine aminotransferase (ALT), U/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
aspartate aminotransferase
aspartate aminotransferase (AST), U/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
Total cholesterol
Total cholesterol (TC), mmol/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
Triglycerides
Triglycerides (TG), mmol/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
high-density lipoprotein cholesterol
high-density lipoprotein cholesterol (HDL-c), mmol/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
low-density lipoprotein cholesterol
low-density lipoprotein cholesterol (LDL-c), mmol/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
Creatinine
Creatinine (Cr), umol/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
serum uric acid
serum uric acid (SUA), umol/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
luteinizing hormone
luteinizing hormone (LH), IU/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
follicle-stimulating hormone
follicle-stimulating hormone (FSH), IU/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
pituitary prolactin
pituitary prolactin (PRL), mIU/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
total testosterone
total testosterone (TT), ng/ml
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
free testosterone
free testosterone (FT), pg/ml
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
Sex hormone binding globulin
Sex hormone binding globulin (SHBG), nmol/L
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
Androstenedione
Androstenedione (AD), ng/ml
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
dehydroepiandrosterone sulfate
dehydroepiandrosterone sulfate (DHEAS), ug/dl
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
controlled attenuation parameter
controlled attenuation parameter (CAP), dB/m
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
liver stiffness measurement
liver stiffness measurement (LSM), kPa
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
total body fat
percentage of total body fat, %
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
total body lean
percentage of total body lean, %
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
total fat mass
total fat mass, kg
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
total lean mass
total lean mass, kg
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
the change in subcutaneous adipose tissue
the change in subcutaneous adipose tissue (pretreatment-post-treatment) after achievement of the weight loss target
Time frame: from randomization to the time of achievement of the weight loss target, an average of 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.